Skip to main content
SpringerLink
Log in

Clinical Trial Simulation and Quantitative Pharmacology

  • Chapter
  • First Online:
Clinical Trial Simulations

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 1))

  • 2605 Accesses

Abstract

Clinical trial simulation (CTS) concepts and techniques comprise a specialized niche in the field of quantitative pharmacology, enabled by advanced pharmacostatistical data analytic and simulation techniques. Since the first demonstrations of the value of CTS in drug development programs, these techniques have been embraced and advanced by both biopharmaceutical developers and regulatory agencies. In this introductory chapter, the editors discuss important trends that have been impacted by CTS, elaborated in more detail in subsequent chapters.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Clewell HJ, Andersen ME, Wills RJ, Latriano L (1997) A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:S77–S85

    Article  PubMed  Google Scholar 

  • Comté L, Vansteelandt S, Tousset E, Baxter G, Vrijens B (2009) Linear and loglinear structural mean models to evaluate the benefits of an on-demand dosing regimen. Clin Trials 6:403–415

    Article  PubMed  Google Scholar 

  • Dobin RE (2000) Regulation of the medical use of psychedelics and marijuana. PhD, Harvard University, pp 168–169

    Google Scholar 

  • Duan J, Jackson A, Zhao P (2010) Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J Clin Pharmacol. Published online before print September 23, 2010 doi: 10,1177/0091270010377200

    Google Scholar 

  • Egan TD, Muir K, Hermann DJ, Stanski DR, Shafer SL (2001) The electroencephalogram (EEG) and clinical measures of opioid potency: defining the EEG-clinical potency relationship (‘fingerprint’) with application to remifentanil. Int J Pharm Med 15(1–2):8–13

    Google Scholar 

  • European Commission: Seventh Framework Programme (2010) Ascertaining barriers for compliance: policies for safe, effective and cost-effective use of medicines in Europe. Available from http://abcproject.eu/index.php?page=project. Accessed June 2010

  • European Medicines Agency (2008) EMEA workshop on modeling in paediatric medicines. Available from http://www.ema.europa.eu/meetings/conferences/1415apr08.htm. Accessed June 2010

  • FDA (2000) Clinical pharmacology and biopharmaceutics review: NDA 21-108 0.02% Tretinoin emollient cream (RENOVA ®). Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-108_Renova_BioPharmr.pdf, p 19. Accessed June 2010

  • FDA (2004) Clinical pharmacology and biopharmaceutics review template. Available from http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM073007.pdf. Accessed June 2010

  • FDA (2005) Guidance for industry clinical lactation studies – study design, data analysis, and recommendations for labeling. Available from http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127505.pdf. Accessed June 2010

  • FDA (2008) FDA approved label: ORTHO TRI-CYCLEN ® Lo Tablets (norgestimate/ethinyl estradiol) Raritan. Ortho Womens Health and Urology, New Jersey

    Google Scholar 

  • FDA (2009) Guidance for industry end-of-phase 2A meetings. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079690.pdf. Accessed June 2010

  • FDA (2010a) Pharmacometrics at FDA. Available from http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm167032.htm. Accessed June 2010

  • FDA (2010b). FDA approved drug label: Prolia ®, prescribing information. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf. Accessed June 2010

  • Gobburu JV (2010) Pharmacometrics (2020) J Clin Pharmacol 50(Supp 9):151S–157S, doi: 10.1177/0091270010376977

    Google Scholar 

  • Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA (1998) The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64:672–683

    Article  PubMed  CAS  Google Scholar 

  • Harter JG, Peck CC (1991) Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci 618:563–571

    Article  PubMed  CAS  Google Scholar 

  • Holford NHG, Kimko H, Monteleone JP, Peck CC (2000) Simulation of Clinical Trials. Annu Rev Pharmacol Toxicol 40:209–234

    Article  PubMed  CAS  Google Scholar 

  • Huang W, Lee SL, Yu LX (2009) Mechanistic approaches to predicting oral drug absorption. AAPS J 11(2):217–224

    Article  PubMed  CAS  Google Scholar 

  • Kastrissios H, Girard P (2003) Protocol deviations and execution models. In: Kimko H, Duffell SB (eds) Simulation for designing clinical trials – a pharmacokinetic-pharmacodynamic modeling perspective. Marcel Dekker, New York

    Google Scholar 

  • Kimko H, Duffull SB (2003) Simulation for designing clinical trials – a pharmacokinetic-pharmacodynamic modeling perspective. Marcel Dekker, New York

    Google Scholar 

  • Lasagna L, Hutt BB (1991) Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B (eds) Patient compliance in medical practice and clinical trials. Raven, New York, p 401

    Google Scholar 

  • Lionberger R (2008) FDA critical path initiatives: opportunities for generic drug development. AAPS J 10(1):103–109

    Article  PubMed  Google Scholar 

  • Lionberger R (2009) Regulatory applications of modelling and simulations at FDA. Presented at Conference of Physiologically Based Pharmacokinetic Modeling in Drug Development and Regulation, Arlington VA, April 6. http://www.thehamner.org/docs/pbpk_09/Day1.Lionberger.pdf. Accessed June 2010

  • Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, and for the AMG 162 Bone Loss Study Group (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222–229

    Google Scholar 

  • Oo C, Chen YC (2009) The need for multiple doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug-Drug Interaction Study. J Clin Pharmacol 49(3):368–369

    Article  PubMed  Google Scholar 

  • Peck CC (1997) Drug development: improving the process. Food Drug Law J 52(2):163–167

    PubMed  CAS  Google Scholar 

  • Peck CC (1999) Noncompliance and clinical trials: regulatory perspective. In: Metry JM, Meyer UA (eds) Drug regimen compliance: issues in clinical trials and patient management. Wiley, Chichester, pp 97–102

    Chapter  Google Scholar 

  • Pharsight Reference Library (2010) Bibliography for computer-assisted trial design. Available from http://www.pharsight.com/library/soln_catd_bibliography.pdf. Accessed June 2010

  • Powell JR, Gobburu JV (2007) Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther 82(1):97–102

    Article  PubMed  CAS  Google Scholar 

  • Rowland M, Balant L, Peck C (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report. AAPS J 6(1):6–10

    Google Scholar 

  • Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev of Pharmacol and Toxicol 51:45–73

    Article  PubMed  CAS  Google Scholar 

  • Sanathanan L, Peck C (1991) The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control Clin Trials 12:780–794

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB (1991) The intellectual health of clinical drug evaluation. Clin Pharmacol Ther 50(1):4–9

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmcol Ther 61(3):275–291

    Article  CAS  Google Scholar 

  • Sheiner LB, Hashimoto Y, Beal SL (1991) A simulation study comparing designs for dose ranging. Stat Med 10(3):303–321

    Article  PubMed  CAS  Google Scholar 

  • UCSF-CDDS-DIA (2008) Conference: improving drug development using patient adherence data in clinical trials. Available from http://bts.ucsf.edu/cdds/pdfs/dia_patient_adherence.pdf. Accessed June 2010

  • Urquhart J (1991) Compliance and clinical trials. Lancet 337(8751):1224–1225

    Article  PubMed  CAS  Google Scholar 

  • Urquhart J (2003) History-informed perspectives on the modeling and simulation of therapeutic drug actions. In: Kimko H, Duffull SB (eds) Simulation for designing clinical trials - a pharmacokinetic-pharmacodynamic modeling perspective. Marcel Dekker, New York

    Google Scholar 

  • Urquhart J, Vrijens B (2005) New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hosp Pharm Sci 11(5):103–106

    Google Scholar 

  • Vrijens B, Goetghebeur E (1999) The impact of compliance in pharmacokinetic studies. Stat Methods Med Res 8:247–262

    Article  PubMed  CAS  Google Scholar 

  • Vrijens B, Goetghebeur E, de Klerk E, Rode R, Mayer S, Urquhart J (2005a) Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 24(17):2719–2731

    Article  PubMed  Google Scholar 

  • Vrijens B, Gross R, Urquhart J (2005b) The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. Basic Clin Pharmacol 96(3):225–227

    Article  CAS  Google Scholar 

  • Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J (2005c) Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 45:461–467

    Article  PubMed  CAS  Google Scholar 

  • Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J 336:1114–1117

    Article  Google Scholar 

  • Zhang L, Reynolds KS, Zhao P, Huang SM (2010) Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 243(2):134–145

    Article  PubMed  CAS  Google Scholar 

  • Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49(3):351–359

    Article  PubMed  CAS  Google Scholar 

  • Zhao P, Zhang L, Lesko J, Huang S (2010) Utility of physiologically-based pharmacokinetic modeling and simulation in drug development and challenges for regulatory reviews. Clin Pharmacol Ther 87:S72

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Drug Development Science, Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California at San Francisco, 5955 Balm Ridge Way, San Luis Obispo, CA, 93401, USA

    Carl C. Peck

Authors
  1. Carl C. Peck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holly H. C. Kimko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl C. Peck .

Editor information

Editors and Affiliations

  1. Department of Advanced Modeling & Simula, Janssen Research & Development, LLC, Route 202 S. 920, Raritan, 08869, New Jersey, USA

    Holly H. C. Kimko

  2. Dept. Biopharmaceutical Sciences, University of California, San Francisco, Parnassus Ave. 513, San Francisco, 94143-0446, California, USA

    Carl C. Peck

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Peck, C.C., Kimko, H.H.C. (2011). Clinical Trial Simulation and Quantitative Pharmacology. In: Kimko, H., Peck, C. (eds) Clinical Trial Simulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7415-0_1

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation